Cellaris's non-integrative lentiviral vector (LVNI) has cleared a critical safety milestone: a high-sensitivity Nested Alu-PCR assay confirmed a complete absence of genomic integration following exposure. The result substantially reduces the theoretical risk of insertional mutagenesis associated with traditional viral CAR-T platforms.
Why integration matters
Integrative lentiviruses are a workhorse of the gene-therapy field, but the integration step itself is what creates the long-running concern about insertional mutagenesis — the small but real possibility that a vector lands inside a tumour-suppressor or oncogene and causes harm years after dosing. For applications where CAR persistence does not need to be permanent, removing integration removes that risk class entirely.
The assay
To validate transience, the team ran a Nested Alu-PCR assay, which targets host-virus junctions with sensitivity high enough to detect low-frequency integration events. The setup included three controls:
- Integration Risk control — confirms the assay can pick up host-virus junctions when they exist.
- Standard LV reference — a known integrative lentivirus, used as the positive control.
- LVNI samples — the candidate non-integrative vector.
Result
Standard LV integration was robustly detected by the assay, validating its sensitivity. Under the same conditions, the LVNI samples returned a complete absence of host-virus junctions — consistent with the vector's intended episomal-only behaviour.
For safety-sensitive indications — autoimmune disease, repeat-dose oncology, paediatric programmes — a vector that can be cleanly proven not to integrate changes the risk-benefit calculus.
What it unlocks
With integration risk off the table for the non-integrative variant, Cellaris can pursue clinical use cases where transient or repeat dosing is preferable to durable integration — including immunomodulation in autoimmune disease, controlled-duration oncology, and next-generation vaccine platforms.
This work was presented at the 9th CAR-TCR Summit Europe alongside the platform's targeting and efficacy data. Full methodological detail is available on the Science page.
Back to news